These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30343732)

  • 1. Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review.
    Tunnicliffe DJ; Palmer SC
    Am J Kidney Dis; 2018 Nov; 72(5):756-757. PubMed ID: 30343732
    [No Abstract]   [Full Text] [Related]  

  • 2. Updates on the treatment of lupus nephritis.
    Bomback AS; Appel GB
    J Am Soc Nephrol; 2010 Dec; 21(12):2028-35. PubMed ID: 21051743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.
    Burchardi C; Schlöndorff D
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):314-5. PubMed ID: 16932452
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide.
    Matsuyama N; Morimoto S; Tokano Y; Amano H; Nozawa K; Isonuma H; Hashimoto H; Takasaki Y
    Intern Med; 2010; 49(9):823-8. PubMed ID: 20453401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
    Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
    J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.
    Lau KK; Ault BH; Jones DP; Butani L
    J Pediatr Health Care; 2008; 22(5):282-8. PubMed ID: 18761229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapies for proliferative lupus nephritis.
    Gelber AC; Christopher-Stine L; Fine DM
    N Engl J Med; 2004 Jun; 350(24):2518-20; author reply 2518-20. PubMed ID: 15195341
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide.
    Elliott JR; Manzi S
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):354-5. PubMed ID: 16932717
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential therapies for proliferative lupus nephritis.
    Yee CS; Gordon C
    N Engl J Med; 2004 Jun; 350(24):2518-20; author reply 2518-20. PubMed ID: 15190147
    [No Abstract]   [Full Text] [Related]  

  • 11. The safety of pharmacological treatment options for lupus nephritis.
    Velo-García A; Ntatsaki E; Isenberg D
    Expert Opin Drug Saf; 2016 Aug; 15(8):1041-54. PubMed ID: 27159360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?
    Bomback AS
    Am J Kidney Dis; 2018 Nov; 72(5):758-760. PubMed ID: 30343733
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.
    Karassa FB; Isenberg DA
    N Engl J Med; 2001 Feb; 344(5):382-3. PubMed ID: 11195799
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy for lupus nephritis--something old, something new.
    Balow JE; Austin HA
    N Engl J Med; 2004 Mar; 350(10):1044-6. PubMed ID: 14999117
    [No Abstract]   [Full Text] [Related]  

  • 16. Current management of lupus nephritis.
    Houssiau FA; Lauwerys BR
    Best Pract Res Clin Rheumatol; 2013 Jun; 27(3):319-28. PubMed ID: 24238689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.
    Urowitz MB; Ibañez D; Ali Y; Gladman DD
    J Rheumatol; 2007 Jul; 34(7):1491-6. PubMed ID: 17610320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapies for proliferative lupus nephritis.
    Farhey Y; Hess E
    N Engl J Med; 2004 Jun; 350(24):2518-20; author reply 2518-20. PubMed ID: 15195342
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil for lupus nephritis.
    McCune WJ
    N Engl J Med; 2005 Nov; 353(21):2282-4. PubMed ID: 16306526
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.